Health Care & Life Sciences » Biotechnology | RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6.30
844.00
317.60
769.50
181.70
237.30
Other Current Assets
26.30
86.50
24.30
79.90
35.40
36.60
Total Current Assets
32.60
930.60
341.90
849.40
217.20
273.90
Net Property, Plant & Equipment
4.40
12.90
10.50
7.20
4.20
1.40
Other Assets
5.80
5.80
5.80
5.80
5.80
5.80
Total Assets
42.70
949.20
358.20
862.40
227.10
281
ST Debt & Current Portion LT Debt
-
-
-
300.00
591.00
Accounts Payable
577.20
232.60
141.10
75.70
66.50
Other Current Liabilities
39.00
177.00
217.90
284.10
1,495.60
Total Current Liabilities
616.30
409.60
359.00
659.80
2,153.10
Long-Term Debt
647.90
1,851.20
688.90
512.00
43.80
Other Liabilities
400.00
400.00
6,052.70
5,757.20
2,146.50
Total Liabilities
1,664.10
2,660.80
7,100.60
6,929.00
4,343.40
Common Equity (Total)
1,621.40
1,711.60
6,742.40
6,066.60
4,116.30
Total Shareholders' Equity
1,621.40
1,711.60
6,742.40
6,066.60
4,116.30
Total Equity
1,621.40
1,711.60
6,742.40
6,066.60
4,116.30
Liabilities & Shareholders' Equity
42.70
949.20
358.20
862.40
227.10

About RegeneRX Biopharmaceuticals

View Profile
Address
15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Website http://www.regenerx.com
Updated 07/08/2019
RegeneRx Biopharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The firm evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. Its products include RGN-259, RGN-352, and RGN-137.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.